Cancer Chemotherapy and Pharmacology

, Volume 79, Issue 3, pp 467–477 | Cite as

Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting

  • Joseph V. PergolizziJr.
  • Robert Taylor
  • Jo Ann LeQuang
  • Gianpietro Zampogna
  • Robert B. Raffa
Review Article


Chemotherapy-induced nausea and vomiting (CINV) is a prevalent, distressing, and burdensome side effect of cancer chemotherapy. It is estimated to affect the majority of patients receiving certain anti-cancer drug regimens and can be treatment-limiting, even for life-saving medications. Despite seemingly numerous options, such as antimuscarinic anticholinergics, antihistamines, 5-HT3 receptor antagonists, dopamine receptor antagonists, and neurokinin-1 receptor antagonists, preventative therapies are often inadequately effective, particularly for “delayed CINV”—leaving an important unmet clinical need. Cannabinoid receptor agonists, by virtue of their unique mechanism of action and efficacy and safety data reported in clinical trials, appear to offer a useful additional option. The mechanistic value of cannabinoids has been well known for many years, but these agents may have been underutilized in the past because of the notoriety and legal status of marijuana. While botanical marijuana contains nearly 500 components, including the psychoactive tetrahydrocannabinol (THC), nabilone is an established, single-entity synthetic cannabinoid receptor agonist that has become the focus of renewed interest. We review the basic pharmacology and clinical trial data of nabilone for use in prophylaxis and treatment of CINV.


CINV Emesis Nabilone Chemotherapy Cannabinoids 


  1. 1.
    Wiser W, Berger A (2005) Practical management of chemotherapy-induced nausea and vomiting. Int Soc Cell 19(5):637–645Google Scholar
  2. 2.
    Salsman JM, Grunberg SM, Beaumont JL et al (2012) Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Cancer Netw JNCCN 10(2):149–157PubMedGoogle Scholar
  3. 3.
    Haiderali A, Menditto L, Good ML, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer 19(6):843–851CrossRefPubMedGoogle Scholar
  4. 4.
    Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22(1):30–38CrossRefPubMedGoogle Scholar
  5. 5.
    Grassi L, Berardi MA, Ruffilli F et al (2015) Role of Psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study. Psychother Psychosom 84(6):339–347CrossRefPubMedGoogle Scholar
  6. 6.
    Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117CrossRefPubMedGoogle Scholar
  7. 7.
    Ettinger DS, Grunberg SM, Hauber AB, Mohamed AF (2009) Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings. Support Care Cancer 17(4):405–411CrossRefPubMedGoogle Scholar
  8. 8.
    Hornby P. Central neurocircuitry associated with emesis. Am J Med Genet 2001;111(Suppl 8 A):106S–112SGoogle Scholar
  9. 9.
    Jordan K, Warr DG, Hinke A, Sun L, Hesketh PJ (2016) Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis. Support Care Cancer 24:1941–1954CrossRefPubMedGoogle Scholar
  10. 10.
    Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12(9):1143–1150CrossRefPubMedGoogle Scholar
  11. 11.
    Hesketh P (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494CrossRefPubMedGoogle Scholar
  12. 12.
    Andrews P, Sanger G (2002) Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol 2(6):650–656CrossRefPubMedGoogle Scholar
  13. 13.
    Lummis S (2012) 5-HT(3) receptors. J Biol Chem 287(48):40239–40245CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Darmani N, Ray A (2009) Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev 109(7):3158–3199CrossRefPubMedGoogle Scholar
  15. 15.
    Andrews P, Horn C (2006) Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 125(1–2):100–115CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Apfel CC, Heidrich FM, Jukar-Rao S et al (2012) Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 109(5):742–753CrossRefPubMedGoogle Scholar
  17. 17.
    Gan TJ, Meyer TA, Apfel CC et al (2007) Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 105(6):1615–1628 (table of contents)CrossRefPubMedGoogle Scholar
  18. 18.
    Apfel CC, Kranke P, Eberhart LH, Roos A, Roewer N (2002) Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 88(2):234–240CrossRefPubMedGoogle Scholar
  19. 19.
    Apfel CC, Kranke P, Greim CA, Roewer N (2001) What can be expected from risk scores for predicting postoperative nausea and vomiting? Br J Anaesth 86(6):822–827CrossRefPubMedGoogle Scholar
  20. 20.
    Gan TJ, Diemunsch P, Habib AS et al (2014) Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 118(1):85–113CrossRefPubMedGoogle Scholar
  21. 21.
    Rusch D, Eberhart L, Biedler A, Dethling J, Apfel CC (2005) Prospective application of a simplified risk score to prevent postoperative nausea and vomiting. Can J Anesth 52(5):478–484CrossRefPubMedGoogle Scholar
  22. 22.
    Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124CrossRefPubMedGoogle Scholar
  23. 23.
    Fero KE, Jalota L, Hornuss C, Apfel CC (2011) Pharmacologic management of postoperative nausea and vomiting. Expert Opin Pharmacother 12(15):2283–2296CrossRefPubMedGoogle Scholar
  24. 24.
    Markman M (2002) Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med 609–610(612):615–607Google Scholar
  25. 25.
    Rojas C, Slusher BS (2015) Mechanisms and latest clinical studies of new NK receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron). Cancer Treat Rev 41(10):904–913. doi: 10.1016/j.ctrv.2015.09.005 CrossRefPubMedGoogle Scholar
  26. 26.
    Fauser AA, Fellhauer M, Hoffmann M, Link H, Schlimok G, Gralla RJ (1999) Guidelines for anti-emetic therapy: acute emesis. Eur J Cancer 35(3):361–370CrossRefPubMedGoogle Scholar
  27. 27.
    National Comprehensive Cancer Network (2015) NCCN Clinical Practice Guidelines in Oncology: antiemesis. Fort Washginton. National Comprehensive Cancer Network, PAGoogle Scholar
  28. 28.
    Hesketh PJ, Van Belle S, Aapro M et al (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8):1074–1080CrossRefPubMedGoogle Scholar
  29. 29.
    Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971–2994CrossRefPubMedGoogle Scholar
  30. 30.
    Ettinger DS, Armstrong DK, Barbour S et al (2009) Antiemesis. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 7(5):572–595Google Scholar
  31. 31.
    Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. BioMed Res Int 2015:595894CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15(11):1293–1300CrossRefPubMedGoogle Scholar
  33. 33.
    Olver I, Paska W, Depierre A et al (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 7(9):945–952CrossRefPubMedGoogle Scholar
  34. 34.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098CrossRefPubMedGoogle Scholar
  35. 35.
    Gilmore JW, Peacock NW, Gu A et al (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract Am Soc Clin Oncol 10(1):68–74CrossRefGoogle Scholar
  36. 36.
    Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992CrossRefPubMedGoogle Scholar
  37. 37.
    Gralla RJ, Roila F, Tonato M et al (2005) The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants. Support Care Cancer 13(2):77–79CrossRefPubMedGoogle Scholar
  38. 38.
    Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21 Suppl 5:v232–v243Google Scholar
  39. 39.
    Hesketh PJ, Bohlke K, Lyman GH et al (2016) Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol 34(4):381–386. doi: 10.1200/JCO.2015.64.3635 CrossRefPubMedGoogle Scholar
  40. 40.
    Pertwee RG, Howlett AC, Abood ME et al (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62(4):588–631CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561–564CrossRefPubMedGoogle Scholar
  42. 42.
    Yang H, Zhou J, Lehmann C (2016) GPR55—a putative “type 3” cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol 27(3):297–302. doi: 10.1515/jbcpp-2015-0080 CrossRefPubMedGoogle Scholar
  43. 43.
    Svizenska I, Dubovy P, Sulcova A (2008) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures—a short review. Pharmacol Biochem Behav 90(4):501–511CrossRefPubMedGoogle Scholar
  44. 44.
    Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61–65CrossRefPubMedGoogle Scholar
  45. 45.
    Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160(3):467–479CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Atwood BK, Straiker A, Mackie K (2012) CB(2) cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. Neuropharmacology 63(4):514–523CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Atwood BK, Straiker A, Mackie K (2012) CB(2): therapeutic target-in-waiting. Prog Neuro-psychopharmacol Biol Psychiatry 38(1):16–20CrossRefGoogle Scholar
  48. 48.
    Maccarrone M, Bab I, Biro T et al (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36(5):277–296CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Capettini LS, Savergnini SQ, da Silva RF et al (2012) Update on the role of cannabinoid receptors after ischemic stroke. Mediat Inflamm 2012:824093CrossRefGoogle Scholar
  50. 50.
    Kramer JL (2015) Medical marijuana for cancer. CA Cancer J Clin 65(2):109–122CrossRefPubMedGoogle Scholar
  51. 51.
    Ettinger D, Kirkegaard S, Roeland EJ et al (2015) NCCN Clinical Practice Guidelines in Oncology: antiemesis. Accessed 29 Oct 2015
  52. 52.
    Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Basch E, Prestrud AA, Hesketh PJ, Kris MG, Somerfield MR, Lyman GH (2012) Antiemetic use in oncology: updated guideline recommendations from ASCO. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting. 2012:532–540Google Scholar
  54. 54.
    Todaro B (2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Cancer Netw 10(4):487–492Google Scholar
  55. 55.
    Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313(24):2474–2483CrossRefPubMedGoogle Scholar
  56. 56.
    Parmar JR, Forrest BD, Freeman RA (2016) Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Res Soc Admin Pharm 12(4):638–654. doi: 10.1016/j.sapharm.2015.09.002 CrossRefGoogle Scholar
  57. 57.
    Owens B (2015) Drug development: the treasure chest. Nature 525(7570):6–8CrossRefGoogle Scholar
  58. 58.
    Chang AE, Shiling DJ, Stillman RC et al (1979) Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91(6):819–824CrossRefPubMedGoogle Scholar
  59. 59.
    Chang AE, Shiling DJ, Stillman RC et al (1981) A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47(7):1746–1751CrossRefPubMedGoogle Scholar
  60. 60.
    Canadian Agency for Drugs and Technologies in Health (2014) Nabilone for non-chemotherapy associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines. 2014 Canadian Agency for Drugs and Technologies in Health, OttawaGoogle Scholar
  61. 61.
    Nabilone (Cesamet) Package Insert (2006) Valeant Pharmaceuticals North America, San DiegoGoogle Scholar
  62. 62.
    Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Invest Drugs 17(1):85–95CrossRefGoogle Scholar
  63. 63.
    Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ (Clin Res Ed) 323(7303):16–21CrossRefGoogle Scholar
  64. 64.
    Whiting P, Wolff R, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473CrossRefPubMedGoogle Scholar
  65. 65.
    Herman TS, Jones SE, Dean J et al (1977) Nabilone: a potent antiemetic cannabinol with minimal euphoria. Biomedicine 27(9–10):331–334PubMedGoogle Scholar
  66. 66.
    Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300(23):1295–1297CrossRefPubMedGoogle Scholar
  67. 67.
    Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981;21(8–9 Suppl):64S–69SGoogle Scholar
  68. 68.
    Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48(5):657–663CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Crawford SM, Buckman R (1986) Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 3(1):39–42PubMedGoogle Scholar
  70. 70.
    Cunningham D, Bradley CJ, Forrest GJ et al (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24(4):685–689CrossRefPubMedGoogle Scholar
  71. 71.
    Niederle N, Schutte J, Schmidt CG (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 64(8):362–365CrossRefPubMedGoogle Scholar
  72. 72.
    Pomeroy M, Fennelly JJ, Towers M (1986) Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 17(3):285–288CrossRefPubMedGoogle Scholar
  73. 73.
    Valeant Pharmaceuticals (2006) Cesamet (nabilone): innovations in omnineuromodulation for chemotherapy-induced nausea and vomiting. Accessed 6 Nov 2015
  74. 74.
    Davis DP (2016) Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw 14:915–922PubMedGoogle Scholar
  75. 75.
    Tafelski S, Hauser W, Schafer M (2016) Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz 30:14. doi: 10.1007/s00482-015-0092-3 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Joseph V. PergolizziJr.
    • 1
  • Robert Taylor
    • 1
  • Jo Ann LeQuang
    • 1
  • Gianpietro Zampogna
    • 1
  • Robert B. Raffa
    • 2
  1. 1.NEMA Research, Inc.NaplesUSA
  2. 2.University of Arizona College of PharmacyTucsonUSA

Personalised recommendations